Literature DB >> 16785109

Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.

R Eleopra1, V Tugnoli, R Quatrale, O Rossetto, C Montecucco, D Dressler.   

Abstract

Botulinum neurotoxin (BoNT) serotype A is commonly used in the treatment of focal dystonia, but some patients are primarily or become secondarily resistant to it. Consequently, other serotypes have to be used when immuno-resistance is proven. In the literature, patients with focal dystonia have been treated with BoNT serotype F with clinical benefit but with short lasting effects. Recently, BoNT serotype C has been used with positive clinical outcome. An update on the clinical use of BoNT serotype F and BoNT serotype C is provided.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16785109     DOI： 10.1007/bf03033930

Source DB:  PubMed          Journal:  Neurotox Res        ISSN： 1029-8428            Impact factor:   3.911


  32 in total

1.  Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial.

Authors:  T Mezaki; R Kaji; M F Brin; M Hirota-Katayama; T Kubori; T Shimizu; J Kimura
Journal:  Mov Disord       Date:  1999-11       Impact factor: 10.338

Review 2.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 3.  Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

4.  Botulinum toxin type B in the treatment of cervical dystonia: a pilot study.

Authors:  J K Tsui; M Hayward; E K Mak; M Schulzer
Journal:  Neurology       Date:  1995-11       Impact factor: 9.910

5.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

Authors:  M F Brin; M F Lew; C H Adler; C L Comella; S A Factor; J Jankovic; C O'Brien; J J Murray; J D Wallace; A Willmer-Hulme; M Koller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

6.  Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.

Authors:  C Sankhla; J Jankovic; D Duane
Journal:  Mov Disord       Date:  1998-01       Impact factor: 10.338

7.  Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.

Authors:  P E Greene; S Fahn
Journal:  Mov Disord       Date:  1993-10       Impact factor: 10.338

8.  Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response.

Authors:  P A Hanna; J Jankovic
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

Review 9.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

10.  Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.

Authors:  R Eleopra; V Tugnoli; O Rossetto; C Montecucco; D De Grandis
Journal:  Neurosci Lett       Date:  1997-03-14       Impact factor: 3.046
View more
  23 in total

Review 1.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 2.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

Review 3.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

4.  Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity.

Authors:  Dirk Dressler; Lizhen Pan; Fereshte Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2018-07-31       Impact factor: 3.575

5.  Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Authors:  Sabine Pellett; William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Toxicon       Date:  2017-12-19       Impact factor: 3.033

6.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

7.  Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin.

Authors:  Dongsheng Wang; Zhen Zhang; Min Dong; Shihu Sun; Edwin R Chapman; Meyer B Jackson
Journal:  Biochemistry       Date:  2011-03-18       Impact factor: 3.162

8.  Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  FEBS Lett       Date:  2019-07-04       Impact factor: 4.124

9.  The Structure and Classification of Botulinum Toxins.

Authors:  Min Dong; Pål Stenmark
Journal:  Handb Exp Pharmacol       Date:  2021

10.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.